<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226991</url>
  </required_header>
  <id_info>
    <org_study_id>1182.102</org_study_id>
    <nct_id>NCT02226991</nct_id>
  </id_info>
  <brief_title>Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers</brief_title>
  <official_title>A Single-centre, Open-label Study to Assess the Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration When Tipranavir/Ritonavir Are Administered at Doses 500 mg/200 mg BID to Steady-state in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the effects of steady-state Efavirenz (600 mg QD) on the steady-state
      pharmacokinetics of Tipranavir (500 mg BID) coadministered with Ritonavir (200 mg BID)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration at steady state (Cmax)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma at 12 hours after administration (Cp12h)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
    <description>Tipranavir (TPV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Last measured drug concentration in plasma (Cplast)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
    <description>Ritonavir (RTV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration time curve from 0-12 hours (AUC0-12h)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough plasma concentration (Cmin)</measure>
    <time_frame>before drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration (tmax)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 38 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 38 days after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/RTV/EFV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>TPV/RTV/EFV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>TPV/RTV/EFV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>TPV/RTV/EFV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects between 18 and 60 years of age inclusive

          2. A Body Mass Index (BMI) between 18 and 29.9 kg/m2

          3. Signed informed consent prior to trial participation

          4. Ability to swallow multiple large capsules without difficulty

          5. Acceptable laboratory values that indicate adequate baseline organ function at
             screening visit

               -  Laboratory values are considered to be acceptable if the severity of any
                  parameter is ≤Grade 1, based on the Division of AIDS (DAIDS)/AIDS Clinical Trials
                  Group (ACTG) Grading Scale

               -  All abnormal laboratory values &gt;Grade 1 are subject to approval by the BI trial
                  clinical monitor

          6. Acceptable medical history, physical examination, and 12-lead ECG at screening

          7. Willingness to abstain from the following starting 2 weeks prior to administration of
             any study medication and up until the end of the study:

               -  Grapefruit or grapefruit juice, red wine, Seville oranges, St. John's Wort, and
                  Milk Thistle

          8. Willingness to abstain from alcohol starting 3 days prior to administration of any
             study medication up to the end of the study

          9. Willingness to abstain from the following starting 3 days prior to pharmacokinetic
             (PK) sampling:

               -  Garlic supplements and methylxanthine containing foods or drinks (including
                  coffee, tea, cola, energy drinks, chocolate, etc.), apples or apple juice

         10. Willingness to abstain from over-the-counter herbal medications for the duration of
             the study

         11. Must be a non-smoker

         12. Willingness to abstain from vigorous physical exercise during intensive PK days; Days
             10 and 24

         13. Reasonable probability for completion of the study

        Exclusion Criteria:

          1. Female subjects of reproductive potential who:

               -  Have positive serum pregnancy test

               -  Have not been using a barrier method of contraception for at least 3 months prior
                  to participation in the study

               -  Are not willing to use a reliable method of barrier contraception (such as
                  diaphragm with spermicidal cream/jelly or condoms with spermicidal foam), during
                  and 60 days after completion/termination of the trial

               -  Are breast-feeding.

          2. Use of any pharmacological contraceptive (including oral, patch or injectable
             contraceptives) within 1 month prior to Day 1 and for the duration of the study.

             Due to long half-life, subjects using Depo-Provera® within six months prior to Day 1
             will be excluded from participation in this study

          3. Use of hormone replacement therapy within 1 month prior to Day 1 and anytime during
             the study

          4. Participation in another trial with an investigational medicine within 2 months prior
             to Day 1 of this study

          5. Use of any medication listed in Appendix 10.5 within 30 days prior to Day 1 of this
             study

          6. Administration of antibiotics within 15 days prior to Day 1 and anytime during the
             study

          7. History of acute illness within 60 days prior to Day 1

               -  Subjects will be excluded for acute illnesses that occurred more than 60 days
                  prior to Day 1 if, in the opinion of the investigator, the subject does not
                  qualify as a healthy volunteer

          8. Have serological evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV)

          9. Have serological evidence of exposure to HIV

         10. Alcohol or substance abuse within 1 year prior to screening or during the study

         11. Blood or plasma donations within 30 days prior to Day 1 or during the study

         12. Subjects with a history of any illness or allergy that, in the opinion of the
             investigator, might confound the results of the study or pose additional risk in
             administering TPV, RTV or EFV to the subject

         13. History of a psychiatric disorder that required pharmacological or other psychological
             treatment

         14. Subjects who have taken (within 7 days prior to Day 1) any over-the-counter or
             prescription medication that, in the opinion of the investigator in consultation with
             the sponsor's clinical monitor, might interfere with absorption, distribution, or
             metabolism of the study medications

         15. Known hypersensitivity to sulphonamide class of drugs

         16. Known hypersensitivity to TPV, RTV, EFV or antiretroviral drugs (marketed or
             experimental use as part of clinical research studies)

         17. Known elevated liver enzymes in past trials with any compound

         18. Inability to adhere to the protocol

         19. Cautions or warnings in the RTV and EFV package insert which, in the opinion of the
             investigator, constitute grounds for subject exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

